FDA Approved: NPLATE — Supplemental Application (Amgen, Inc)

View source ↗

Summary

FDA approved a supplemental application for NPLATE (romiplostim) from Amgen, approving an update to the product's labeling and/or indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Nplate (romiplostim)

Snippet

SUPPL AP for NPLATE (ROMIPLOSTIM)